Preliminary randomized trial evaluated recombinant human granulocyte colony–stimulating factor for patients with COVID-19 and lymphopenia

Effect of Recombinant Human Granulocyte Colony–Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial – JAMA Internal Medicine

Invited Commentary: Immune Stimulation With Recombinant Human Granulocyte Colony–Stimulating Factor for Coronavirus Disease 2019 (COVID-19)—Beware of Blind Spots

Commentary on Twitter

Preliminary findings from a randomized clinical trial suggest that rhG-CSF treatment should be studied in larger trials and in a broader range of patients with #COVID19 https://t.co/SjsoWOkEXg

— JAMA Internal Medicine (@JAMAInternalMed) September 10, 2020